Antipsychotics (APDs) represent a core treatment for severe mental disorders (SMEs). Providing symptomatic relief, APDs do not exert therapeutic effects on another clinically significant domain of serious mental disorders, cognitive impairment. Moreover, adverse metabolic effects (diabetes, weight gain, dyslipidemia, and increased cardiovascular risk) are common during treatment with APDs. Among pharmacological candidates reversing APD-induced metabolic adverse effects, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs), approved for both diabetes and recently for obesity treatment, stand out due to their favorable effects on peripheral metabolic parameters. Interestingly, GLP-1 RAs are also proposed to have pro-cognitive effects. Particularly in terms of dual therapeutic mechanisms potentially improving both central nervous system (CNS) deficits and metabolic burden, GLP-1 RAs open a new perspective and assume a clinically advantageous position.

Department of Clinical Science Faculty of Medicine University of Bergen Bergen Norway; Department of Medical Biochemistry and Pharmacology Haukeland University Hospital Bergen Norway; Section of Clinical Pharmacology Department of Medical Biochemistry and Pharmacology Haukeland University Hospital Bergen Norway

Department of Pharmacology and Toxicology Faculty of Pharmacy Masaryk University Brno Czech Republic; Department of Clinical Pharmacy Hospital Pharmacy University Hospital Brno Brno Czech Republic

Department of Pharmacology Faculty of Medicine Masaryk University Brno Czech Republic

Citace poskytuje Crossref.org

Olanzapine, but not haloperidol, exerts pronounced acute metabolic effects in the methylazoxymethanol rat model